Literature DB >> 33562846

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review.

Emanuela Martina1, Federico Diotallevi1, Giulia Radi1, Anna Campanati1, Annamaria Offidani1.   

Abstract

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey-Hailey disease, epidermolysis bullosa simplex Weber-Cockayne type, Darier's disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

Entities:  

Keywords:  Darier’s disease; Hailey–Hailey disease; Raynaud phenomenon; alopecia; aquagenic keratoderma; botulinum toxin; dermatology; epidermolysis bullosa simplex Weber–Cockayne type; facial erythema and flushing; focal idiopathic hyperhidrosis; notalgia paresthetica; oily skin; pachyonychia congenita; psoriasis; skin diseases; suppurative hidradenitis

Mesh:

Substances:

Year:  2021        PMID: 33562846      PMCID: PMC7915854          DOI: 10.3390/toxins13020120

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


  190 in total

1.  Notalgia paresthetica: clinical, physiopathological and therapeutic aspects. A study of 12 cases.

Authors:  N Raison-Peyron; L Meunier; M Acevedo; J Meynadier
Journal:  J Eur Acad Dermatol Venereol       Date:  1999-05       Impact factor: 6.166

2.  Successful use of botulinum toxin a for the treatment of neck and anterior chest wall flushing.

Authors:  A B Alexandroff; S A Sinclair; J A A Langtry
Journal:  Dermatol Surg       Date:  2006-12       Impact factor: 3.398

3.  Botulinum toxin--a possible new treatment for axillary hyperhidrosis.

Authors:  K O Bushara; D M Park; J C Jones; H S Schutta
Journal:  Clin Exp Dermatol       Date:  1996-07       Impact factor: 3.470

4.  Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage.

Authors:  Anna Campanati; Emanuela Martina; Katia Giuliodori; Ivan Bobyr; Veronica Consales; Annamaria Offidani
Journal:  Dermatol Ther       Date:  2019-02-10       Impact factor: 2.851

5.  Treatment of notalgia paresthetica with botulinum toxin A: a double-blind randomized controlled trial.

Authors:  Catherine Maari; Philippe Marchessault; Robert Bissonnette
Journal:  J Am Acad Dermatol       Date:  2014-06       Impact factor: 11.527

Review 6.  Rosacea Management.

Authors:  Manal Abokwidir; Steven R Feldman
Journal:  Skin Appendage Disord       Date:  2016-05-18

Review 7.  The place of botulinum toxin type A in the treatment of focal hyperhidrosis.

Authors:  N Lowe; A Campanati; I Bodokh; S Cliff; P Jaen; O Kreyden; M Naumann; A Offidani; J Vadoud; H Hamm
Journal:  Br J Dermatol       Date:  2004-12       Impact factor: 9.302

8.  Botulinum toxin type A in chronic non-dyshidrotic palmar eczema: A side-by-side comparative study.

Authors:  Aisha Ismail; Samar El-Kholy; Carmen Farid
Journal:  J Dermatol       Date:  2020-04-14       Impact factor: 4.005

9.  Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases.

Authors:  Jéssica González-Ramos; Elena Sendagorta-Cudós; Guillermo González-López; Ander Mayor-Ibarguren; Rosa Feltes-Ochoa; Pedro Herranz-Pinto
Journal:  Dermatol Ther       Date:  2015-10-07       Impact factor: 2.851

Review 10.  Immunogenicity of botulinum toxins.

Authors:  Markus Naumann; Lee Ming Boo; Alan H Ackerman; Conor J Gallagher
Journal:  J Neural Transm (Vienna)       Date:  2012-09-25       Impact factor: 3.575

View more
  6 in total

1.  Precisely specifying which botulinum toxin products are used for aesthetic treatments is essential.

Authors:  Andy Pickett
Journal:  J Oral Biol Craniofac Res       Date:  2022-07-19

2.  Botulinum Toxin Type A for Treatment of Forehead Hyperhidrosis: Multicenter Clinical Experience and Review from Literature.

Authors:  Anna Campanati; Emanuela Martina; Stamatis Gregoriou; George Kontochristopoulos; Matteo Paolinelli; Federico Diotallevi; Giulia Radi; Ivan Bobyr; Barbara Marconi; Giulio Gualdi; Paolo Amerio; Annamaria Offidani
Journal:  Toxins (Basel)       Date:  2022-05-27       Impact factor: 5.075

Review 3.  Botulinum Toxin Use for Modulating Neuroimmune Cutaneous Activity in Psoriasis.

Authors:  Marius Nicolae Popescu; Cristina Beiu; Mădălina Gabriela Iliescu; Mara Mădălina Mihai; Liliana Gabriela Popa; Ana Maria Alexandra Stănescu; Mihai Berteanu
Journal:  Medicina (Kaunas)       Date:  2022-06-16       Impact factor: 2.948

Review 4.  Off-Label Use of Botulinum Toxin in Dermatology-Current State of the Art.

Authors:  Miłosz Lewandowski; Zuzanna Świerczewska; Wioletta Barańska-Rybak
Journal:  Molecules       Date:  2022-05-13       Impact factor: 4.927

Review 5.  Complementary Strategies to Promote Hair Regrowth in Post-COVID-19 Telogen Effluvium.

Authors:  Marius Nicolae Popescu; Mihai Berteanu; Cristina Beiu; Liliana Gabriela Popa; Mara Mădălina Mihai; Madalina Gabriela Iliescu; Ana Maria Alexandra Stănescu; Anca Mirela Ionescu
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-04-22

Review 6.  Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update.

Authors:  Marco Pirazzini; Cesare Montecucco; Ornella Rossetto
Journal:  Arch Toxicol       Date:  2022-03-25       Impact factor: 6.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.